
HER2DX Assay Predicts pCR Following Neoadjuvant THP in HER2+ Breast Cancer
High HER2DX genomic assay score was significantly associated with pathologic complete response (pCR) in patients with stage I to III HER2-positive breast cancer treated with neoadjuvant trastuzumab (Herceptin), pertuzumab (Perjeta), and paclitaxel (THP), …